Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
Cancer is one of the most difficult diseases to treat. It is constantly changing, ...
Cancer is one of the most difficult diseases to...
Predictive Oncology is a clinical and translational data pipeline and AI-driven pl...
Predictive Oncology is a clinical and translati...
Livongo Health, Inc. (NASDAQ: LVGO) is a leading Applied Health Signals company em...
Livongo Health, Inc. (NASDAQ: LVGO) is a leadin...
BioSig Technologies is a medical device company developing a proprietary technolog...
BioSig Technologies is a medical device company...
Pluristem Therapeutics Inc. is a clinical-stage biotherapy company using placental...
Pluristem Therapeutics Inc. is a clinical-stage...
Celldex is developing targeted therapeutics to address devastating diseases for wh...
Celldex is developing targeted therapeutics to ...
AGTC is a clinical-stage biotechnology company that uses a proprietary gene therap...
AGTC is a clinical-stage biotechnology company ...
Join the National Investor Network and get the latest information with your interests in mind.